Literature DB >> 17627578

QSAR studies for the pharmacological inhibition of glycogen synthase kinase-3.

Pablo R Duchowicz1, Eduardo A Castro.   

Abstract

The enzyme GSK-3 plays a central role in cells during the phosphorylation of various key regulatory proteins, and consequently pharmacological inhibitors of this enzyme potentially allow the treatment of diseases that include neurodegenerative and bipolar affective disorders, diabetes, and diseases caused by unicellular parasites. Today there is a huge number of reported empirical structure-activity relationships (SAR) that may guide a rational design of more potent and selective inhibitors. However, only a few studies based on Quantitative Structure-Activity Relationships (QSAR) are available for predicting the inhibitor potency against this specific kinase, and they involve mainly molecular modeling and 3D-QSAR. The present review deals with the recent search for a quantitative analysis of GSK-3 inhibition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627578     DOI: 10.2174/157340607781024375

Source DB:  PubMed          Journal:  Med Chem        ISSN: 1573-4064            Impact factor:   2.745


  3 in total

1.  A 3D-QSAR model based screen for dihydropyridine-like compound library to identify inhibitors of amyloid beta (Aβ) production.

Authors:  Venkatarajan S Mathura; Nikunj Patel; Corbin Bachmeier; Michael Mullan; Daniel Paris
Journal:  Bioinformation       Date:  2010-09-20

2.  Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking.

Authors:  Sivaprakasam Prasanna; Pankaj R Daga; Aihua Xie; Robert J Doerksen
Journal:  J Comput Aided Mol Des       Date:  2008-10-07       Impact factor: 3.686

3.  JNK, p38, ERK, and SGK1 Inhibitors in Cancer.

Authors:  Jonas Cicenas; Egle Zalyte; Arnas Rimkus; Dalius Dapkus; Remigijus Noreika; Sigitas Urbonavicius
Journal:  Cancers (Basel)       Date:  2017-12-21       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.